Given more restrictions on later line PARP inhibitor use for patients by BRCA status, would you consider repeat biopsy with somatic testing to identify candidates for second line maintenance therapy following platinum treatment for a patient who is gBRCAwt?  

Does your approach change depending on the patients initial somatic BRCA status?

Answer from: at Academic Institution

Answer from: Medical Oncologist at Academic Institution